Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate

ISSN： 1205-7541

Source： Canadian Journal of Physiology and Pharmacology, Vol.91, Iss.5, 2013-01, pp. : 380-385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prevention of glucocorticoid-induced osteoporosis

By van Brussel MS Bultink IEM Lems WF

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 997-1005

Informa Healthcare

Access to resources Recommend Favorite

Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis – usefulness of alendronate and risedronate

By Iwamoto Jun Takeda Tsuyoshi Sato Yoshihiro

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 16, 2007-11 ,pp. : 2743-2756

Informa Healthcare

Access to resources Recommend Favorite

Pathogenesis and Treatment of Glucocorticoid-Induced Osteoporosis

By Rackoff P.J.

Drugs & Aging, Vol. 12, Iss. 6, 1998-06 ,pp. : 477-484

Adis International

Access to resources Recommend Favorite

Therapeutic patenting for glucocorticoid-induced osteoporosis

By Cooper M.S. Stewart P.M.

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 6, 2000-06 ,pp. : 847-857

Informa Healthcare

Access to resources Recommend Favorite

The prevention and treatment of glucocorticoid-induced osteoporosis in clinical practice

By Walker-Bone Karen Wood Angela Hull Richard Ledingham Joanna M McCrae Fiona C Shaban Ragai Thomas Alastair Mackay Kirsten

Clinical Medicine, Vol. 4, Iss. 5, 2004-09 ,pp. : 431-436

Royal College Of Physicians

Access to resources Recommend Favorite